Senate’s Comparative Effectiveness Language Emphasizes Clinical Over Cost
This article was originally published in The Gray Sheet
Executive Summary
Comparative effectiveness research funding of $1.1 billion passed the House and got approval from the Senate Appropriations Committee as part of an $800 billion-plus economic stimulus package last week; but device firms and some patient and physician groups are pushing for the Senate language to win out when it comes time to reconcile the bills